Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.94 USD | -6.73% |
|
-11.82% | -53.81% |
05-20 | Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index | CI |
05-17 | First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc | CI |
Business Summary
Number of employees: 9
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Sapirstein
CEO | Chief Executive Officer | 63 | 07/10/19 |
Sarah Romano
DFI | Director of Finance/CFO | 44 | 28/02/22 |
Amy Chandler
CMP | Compliance Officer | 56 | - |
Martin Krusin
PRN | Corporate Officer/Principal | - | 31/12/13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 02/03/17 | |
Ed Borkowski
BRD | Director/Board Member | 64 | 30/04/15 |
Alastair Riddell
BRD | Director/Board Member | 74 | 31/08/15 |
James Sapirstein
CEO | Chief Executive Officer | 63 | 07/10/19 |
Mary Coelho
BRD | Director/Board Member | 62 | 10/08/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,475,090 | 2,294,472 ( 92.70 %) | 0 | 92.70 % |
Company contact information
First Wave Biopharma, Inc.
777 Yamato Road Suite 502
33431, Boca Raton
+561 589 7020
http://www.firstwavebio.com![address Entero Therapeutics, Inc.(ENTO)](https://cdn.zonebourse.com/static/address/30506551.png)
Sector
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.81% | 4.8M | |
+34.01% | 51.07B | |
-8.02% | 38.78B | |
+34.86% | 38.86B | |
-11.12% | 26.69B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- ENTO Stock
- Company Entero Therapeutics, Inc.